Clinical traction HypnoVR has a strong clinical footprint with 15 studies showing reduced postoperative length of stay and decreased morphine consumption, highlighting its relevance for hospital systems aiming to improve pain management and opioid-sparing protocols.

Hospital partnerships Existing distribution through UniHA, UGAP, CAHPP, Helpevia, Vivalto Santé, and Elsan indicates a ready channel for expansion in hospital groups and procurement networks, suggesting targeted outreach to these buying committees could accelerate adoption.

Acquisition momentum Recent acquisition of Oncomfort SA expands the product suite and customer base in digital sedation, signaling opportunity to position HypnoVR as part of a broader digital therapy and non-drug pain/anxiety management strategy.

Funding stability With total funding around six to six-and-a-half million dollars and a revenue profile under one million, there is room to leverage investor-backed growth narratives when approaching hospitals seeking innovative, cost-saving solutions.

Tech-enabled care Technical stack and a simple, hygiene-compliant, adaptable hardware approach align with hospital IT and sterilization requirements, facilitating joint deployments with IT, biomedical engineering, and anesthesia departments in surgical settings.